·Î±×ÀÎ Àüü´º½º¿ÀÇǴϾðEnglishÆÊ ¾ÆÄ«µ¥¹ÌÆʽºÅ¸Å¬·´TVÆʵµ¶ó¸®Äí¸£Æ®DPºÎµ¿»êÀλ絿Á¤Event & Çмú¼¼¹Ì³ªµ¶ÀÚÁ¦º¸
°Ë»ö ä¿ëÁ¤º¸ °í¿ë·® OTC 'Æé½Ãµå'AC' FDA ½ÂÀÎ ±â»çÀÔ·Â : 03.09.28 19:01:17 0 °¡ ÇÃÄ£Ãß°¡ ÆĸðƼµò 20mg, ±âÁ¸ ½ÂÀο뷮 2¹è Á¸½¼¾ØÁ¸½¼(J&J)¿Í ¸ÖÅ©ÀÇ Á¶ÀÎÆ® º¥Ã³´Â ¹Ì±¹ FDA°¡ Æé½Ãµå(Pepsid) AC °í¿ë·®À» OTC·Î ½ÃÆÇÇϵµ·Ï ½ÂÀÎÇß´Ù°í ¹ßÇ¥Çß´Ù. Á¦»êÁ¦ÀÎ Æé½Ãµå AC´Â À§ÀåÀå¾Ö¿Í °ü·ÃµÈ ÈäÅëÀ» °æ°¨½ÃÅ°´Â ¾à¹°·Î À̹ø¿¡ ½ÂÀÎµÈ ¿ë·®Àº 20mgÀÌ´Ù. Æé½Ãµå ACÀÇ ¼ººÐÀº ÆĸðƼµò(famotidine). 1995³â¿¡ ÆĸðƼµò 10mgÀÇ OTC ½ÃÆÇÀÌ Ã³À½ ½ÂÀεƾú´Ù. ÆĸðƼµò 20mgÀ» ÇÔÀ¯ÇÏ´Â Æé½Ãµå AC´Â ¸Æ½Ã¸Ø ½ºÆ®·À½º Æé½Ãµå(Maximum Strength Pepsid) AC¶ó´Â »óÇ°¸íÀ» »ç¿ëÇÏ¸ç ¿À´Â 10¿ùºÎÅÍ ¹Ì±¹¿¡¼ º»°Ý ½ÃÆÇÇÒ ¿¹Á¤ÀÌ´Ù. À±ÀÇ°æ ±âÀÚ(ekyeun@dailypharm.com) ±ÛÀÚÅ©±â ¼³Á¤ °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç SM (Oncology) MSL (Á¤±ÔÁ÷) ¹Ù·Î°¡±â Sr. Clinical Operations Manager ¹Ù·Î°¡±â HK inno.N(ÏÁCJÇコÄɾî) ¿À¼Û°øÀå °ü¸®¾à»ç ¸ðÁý ¹Ù·Î°¡±â [Sanofi/»ç³ëÇÇ] RA Specialist ¹Ù·Î°¡±â Clinical Research MSL ¹Ù·Î°¡±â Çѱ¹·Î½´ Clinical Operations Lead ¹Ù·Î°¡±â ȯÀÎÁ¦¾à(ÁÖ) 7¿ù ¼ö½Ãä¿ë(7/1(¿ù)~7/15(¿ù) 13:30±îÁö) ¹Ù·Î°¡±â Á¦Á¶°ü¸® ¾à»ç ¸ðÁý ¹Ù·Î°¡±â Áö¿¤Æĸ¶ °³¹ßº»ºÎ, »ç¾÷°³¹ßÆÀ ä¿ë °ø°í ¹Ù·Î°¡±â [HLBÁ¦¾à] BD, °³¹ß BD °æ·Â ä¿ë ¹Ù·Î°¡±â °ü¸®¾à»ç´Ô ä¿ë°ø°í ¹Ù·Î°¡±â [ÇÍŸ¹Î ´õÇö´ë¼¿ï] »ó´ã ¾à»ç´ÔÀ» ¸ð½Ê´Ï´Ù. ¹Ù·Î°¡±â [»ï¿ø¾àÇ° ¿ï»êÁöÁ¡] °ü¸®¾à»ç´Ô ¸ðÁý°ø°í ¹Ù·Î°¡±â Sr. Clinical Trial Manager ¹Ù·Î°¡±â Market Access Specialist ¹Ù·Î°¡±â Senior RA Specialist ä¿ë ¹Ù·Î°¡±â 0/300 ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸ Ãë±Þ¹æħ | ¹ýÀû°íÁö Copyright ¨Ï Dailypharm 1999-2024,All rights reserved. ¸ÞÀϺ¸³»±â ±â»çÁ¦¸ñ : °í¿ë·® OTC Æé½ÃµåAC FDA ½ÂÀÎ URLº¹»ç ¸ÞÀÏ Æ®À§ÅÍ ÆäÀ̽ººÏ Ä«Ä«¿À½ºÅ丮 Ä«Ä«¿ÀÅå ¹êµå ³×À̹ö
ä¿ëÁ¤º¸ °í¿ë·® OTC 'Æé½Ãµå'AC' FDA ½ÂÀÎ ±â»çÀÔ·Â : 03.09.28 19:01:17 0 °¡ ÇÃÄ£Ãß°¡ ÆĸðƼµò 20mg, ±âÁ¸ ½ÂÀο뷮 2¹è Á¸½¼¾ØÁ¸½¼(J&J)¿Í ¸ÖÅ©ÀÇ Á¶ÀÎÆ® º¥Ã³´Â ¹Ì±¹ FDA°¡ Æé½Ãµå(Pepsid) AC °í¿ë·®À» OTC·Î ½ÃÆÇÇϵµ·Ï ½ÂÀÎÇß´Ù°í ¹ßÇ¥Çß´Ù. Á¦»êÁ¦ÀÎ Æé½Ãµå AC´Â À§ÀåÀå¾Ö¿Í °ü·ÃµÈ ÈäÅëÀ» °æ°¨½ÃÅ°´Â ¾à¹°·Î À̹ø¿¡ ½ÂÀÎµÈ ¿ë·®Àº 20mgÀÌ´Ù. Æé½Ãµå ACÀÇ ¼ººÐÀº ÆĸðƼµò(famotidine). 1995³â¿¡ ÆĸðƼµò 10mgÀÇ OTC ½ÃÆÇÀÌ Ã³À½ ½ÂÀεƾú´Ù. ÆĸðƼµò 20mgÀ» ÇÔÀ¯ÇÏ´Â Æé½Ãµå AC´Â ¸Æ½Ã¸Ø ½ºÆ®·À½º Æé½Ãµå(Maximum Strength Pepsid) AC¶ó´Â »óÇ°¸íÀ» »ç¿ëÇÏ¸ç ¿À´Â 10¿ùºÎÅÍ ¹Ì±¹¿¡¼ º»°Ý ½ÃÆÇÇÒ ¿¹Á¤ÀÌ´Ù. À±ÀÇ°æ ±âÀÚ(ekyeun@dailypharm.com) ±ÛÀÚÅ©±â ¼³Á¤ °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç SM (Oncology) MSL (Á¤±ÔÁ÷) ¹Ù·Î°¡±â Sr. Clinical Operations Manager ¹Ù·Î°¡±â HK inno.N(ÏÁCJÇコÄɾî) ¿À¼Û°øÀå °ü¸®¾à»ç ¸ðÁý ¹Ù·Î°¡±â [Sanofi/»ç³ëÇÇ] RA Specialist ¹Ù·Î°¡±â Clinical Research MSL ¹Ù·Î°¡±â Çѱ¹·Î½´ Clinical Operations Lead ¹Ù·Î°¡±â ȯÀÎÁ¦¾à(ÁÖ) 7¿ù ¼ö½Ãä¿ë(7/1(¿ù)~7/15(¿ù) 13:30±îÁö) ¹Ù·Î°¡±â Á¦Á¶°ü¸® ¾à»ç ¸ðÁý ¹Ù·Î°¡±â Áö¿¤Æĸ¶ °³¹ßº»ºÎ, »ç¾÷°³¹ßÆÀ ä¿ë °ø°í ¹Ù·Î°¡±â [HLBÁ¦¾à] BD, °³¹ß BD °æ·Â ä¿ë ¹Ù·Î°¡±â °ü¸®¾à»ç´Ô ä¿ë°ø°í ¹Ù·Î°¡±â [ÇÍŸ¹Î ´õÇö´ë¼¿ï] »ó´ã ¾à»ç´ÔÀ» ¸ð½Ê´Ï´Ù. ¹Ù·Î°¡±â [»ï¿ø¾àÇ° ¿ï»êÁöÁ¡] °ü¸®¾à»ç´Ô ¸ðÁý°ø°í ¹Ù·Î°¡±â Sr. Clinical Trial Manager ¹Ù·Î°¡±â Market Access Specialist ¹Ù·Î°¡±â Senior RA Specialist ä¿ë ¹Ù·Î°¡±â 0/300 ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸ Ãë±Þ¹æħ | ¹ýÀû°íÁö Copyright ¨Ï Dailypharm 1999-2024,All rights reserved. ¸ÞÀϺ¸³»±â ±â»çÁ¦¸ñ : °í¿ë·® OTC Æé½ÃµåAC FDA ½ÂÀÎ URLº¹»ç ¸ÞÀÏ Æ®À§ÅÍ ÆäÀ̽ººÏ Ä«Ä«¿À½ºÅ丮 Ä«Ä«¿ÀÅå ¹êµå ³×À̹ö
ä¿ëÁ¤º¸ °í¿ë·® OTC 'Æé½Ãµå'AC' FDA ½ÂÀÎ ±â»çÀÔ·Â : 03.09.28 19:01:17 0 °¡ ÇÃÄ£Ãß°¡ ÆĸðƼµò 20mg, ±âÁ¸ ½ÂÀο뷮 2¹è Á¸½¼¾ØÁ¸½¼(J&J)¿Í ¸ÖÅ©ÀÇ Á¶ÀÎÆ® º¥Ã³´Â ¹Ì±¹ FDA°¡ Æé½Ãµå(Pepsid) AC °í¿ë·®À» OTC·Î ½ÃÆÇÇϵµ·Ï ½ÂÀÎÇß´Ù°í ¹ßÇ¥Çß´Ù. Á¦»êÁ¦ÀÎ Æé½Ãµå AC´Â À§ÀåÀå¾Ö¿Í °ü·ÃµÈ ÈäÅëÀ» °æ°¨½ÃÅ°´Â ¾à¹°·Î À̹ø¿¡ ½ÂÀÎµÈ ¿ë·®Àº 20mgÀÌ´Ù. Æé½Ãµå ACÀÇ ¼ººÐÀº ÆĸðƼµò(famotidine). 1995³â¿¡ ÆĸðƼµò 10mgÀÇ OTC ½ÃÆÇÀÌ Ã³À½ ½ÂÀεƾú´Ù. ÆĸðƼµò 20mgÀ» ÇÔÀ¯ÇÏ´Â Æé½Ãµå AC´Â ¸Æ½Ã¸Ø ½ºÆ®·À½º Æé½Ãµå(Maximum Strength Pepsid) AC¶ó´Â »óÇ°¸íÀ» »ç¿ëÇÏ¸ç ¿À´Â 10¿ùºÎÅÍ ¹Ì±¹¿¡¼ º»°Ý ½ÃÆÇÇÒ ¿¹Á¤ÀÌ´Ù. À±ÀÇ°æ ±âÀÚ(ekyeun@dailypharm.com) ±ÛÀÚÅ©±â ¼³Á¤ °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç
0/300 ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸ Ãë±Þ¹æħ | ¹ýÀû°íÁö Copyright ¨Ï Dailypharm 1999-2024,All rights reserved. ¸ÞÀϺ¸³»±â ±â»çÁ¦¸ñ : °í¿ë·® OTC Æé½ÃµåAC FDA ½ÂÀÎ URLº¹»ç ¸ÞÀÏ Æ®À§ÅÍ ÆäÀ̽ººÏ Ä«Ä«¿À½ºÅ丮 Ä«Ä«¿ÀÅå ¹êµå ³×À̹ö